Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics.
Ontology highlight
ABSTRACT: Gene therapies such as onasemnogene abeparvovec for spinal muscular atrophy (SMA) utilize adeno-associated virus 9 (AAV9) for targeted gene delivery, which requires an AAV9 antibody (AAV9-Ab) immunoglobulin G (IgG) ≤1:50 titer threshold. This retrospective cohort study evaluated age-related AAV9-Ab IgG seroprevalence for patients with SMA (part 1) and AAV9-Ab IgG kinetics and time to 1:50 titer threshold in newborns with elevated AAV9-Ab IgG titers (≥1:100) (part 2). A semi-quantitative ELISA assay was used in part 1 (N = 1,323 patients). For patients aged <12 months, 3.9% (n/N = 31/795) had elevated AAV9-Ab IgG titers (≥1:100); prevalence declined with age. In part 2, a new quantitative ELISA (linear mixed effects model) described continuous AAV9-Ab IgG concentrations
SUBMITTER: van Olden RW
PROVIDER: S-EPMC11866128 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA